UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Oruka Therapeutics, Inc. $ORKA

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 517.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 104,310 shares of the company’s stock after buying an additional 87,408 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.16% of Oruka Therapeutics worth $9,927,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ORKA. Algert Global LLC boosted its stake in Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after acquiring an additional 180 shares in the last quarter. Royal Bank of Canada raised its holdings in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after buying an additional 420 shares during the last quarter. AlphaCentric Advisors LLC lifted its stake in shares of Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after buying an additional 626 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after buying an additional 788 shares in the last quarter. 56.44% of the stock is owned by institutional investors.

Insider Buying and Selling at Oruka Therapeutics

In related news, CEO Lawrence Klein sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. This trade represents a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 12,583 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $70.11, for a total transaction of $882,194.13. Following the sale, the director owned 38,743 shares of the company’s stock, valued at $2,716,271.73. This trade represents a 24.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 158,116 shares of company stock worth $13,523,783 over the last 90 days. 23.49% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ORKA shares. UBS Group raised their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Wedbush reissued an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Mizuho set a $120.00 price target on Oruka Therapeutics in a research note on Thursday. Guggenheim reaffirmed a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, BTIG Research reaffirmed a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $133.00.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $92.51 on Monday. The stock has a market capitalization of $6.13 billion, a price-to-earnings ratio of -45.57 and a beta of -0.34. Oruka Therapeutics, Inc. has a 1-year low of $14.66 and a 1-year high of $115.51. The business’s fifty day moving average price is $95.24 and its 200-day moving average price is $69.84.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.